SE9501056D0 - Epithelial adherent lactobacilli - Google Patents

Epithelial adherent lactobacilli

Info

Publication number
SE9501056D0
SE9501056D0 SE9501056A SE9501056A SE9501056D0 SE 9501056 D0 SE9501056 D0 SE 9501056D0 SE 9501056 A SE9501056 A SE 9501056A SE 9501056 A SE9501056 A SE 9501056A SE 9501056 D0 SE9501056 D0 SE 9501056D0
Authority
SE
Sweden
Prior art keywords
pct
mannose
date sep
sec
strain
Prior art date
Application number
SE9501056A
Other languages
English (en)
Swedish (sv)
Inventor
Ingegerd Adlerberth
Siv Ahrne
Bengt Jeppson
Marie-Louise Johansson
Goeran Molin
Agnes Wold
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Priority to SE9501056A priority Critical patent/SE9501056D0/xx
Publication of SE9501056D0 publication Critical patent/SE9501056D0/xx
Priority to JP52834796A priority patent/JP4072646B2/ja
Priority to PCT/SE1996/000372 priority patent/WO1996029083A1/en
Priority to KR1019970706504A priority patent/KR100446482B1/ko
Priority to CA002216150A priority patent/CA2216150C/en
Priority to DE69628288T priority patent/DE69628288T2/de
Priority to US08/913,618 priority patent/US6159465A/en
Priority to AT96908428T priority patent/ATE240738T1/de
Priority to EE9700329A priority patent/EE04097B1/xx
Priority to EP96908428A priority patent/EP0817640B1/en
Priority to HK98111312.1A priority patent/HK1017989B/xx
Priority to AU51665/96A priority patent/AU702705B2/en
Priority to PL96322550A priority patent/PL184037B1/pl
Priority to BR9607538A priority patent/BR9607538A/pt
Priority to CNB961940867A priority patent/CN1138551C/zh
Priority to ES96908428T priority patent/ES2200057T3/es
Priority to NO974371A priority patent/NO974371L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SE9501056A 1995-03-23 1995-03-23 Epithelial adherent lactobacilli SE9501056D0 (sv)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
ES96908428T ES2200057T3 (es) 1995-03-23 1996-03-25 Uso de lactobacillus como adhesivo epitelial.
US08/913,618 US6159465A (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli
EE9700329A EE04097B1 (et) 1995-03-23 1996-03-25 Epiteliaal-adhesiivsed laktobatsillid
KR1019970706504A KR100446482B1 (ko) 1995-03-23 1996-03-25 상피흡착성락토바실러스
CA002216150A CA2216150C (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli
DE69628288T DE69628288T2 (de) 1995-03-23 1996-03-25 Verwendung von epithel-adhärente lactobazillen
JP52834796A JP4072646B2 (ja) 1995-03-23 1996-03-25 上皮接着性乳酸桿菌
AT96908428T ATE240738T1 (de) 1995-03-23 1996-03-25 Verwendung von epithel-adhärente lactobazillen
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli
EP96908428A EP0817640B1 (en) 1995-03-23 1996-03-25 Use of epithelial adhesive lactobacilli
HK98111312.1A HK1017989B (zh) 1995-03-23 1996-03-25 上皮粘附性乳杆菌
AU51665/96A AU702705B2 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli
PL96322550A PL184037B1 (pl) 1995-03-23 1996-03-25 Zastosowanie Lactobacillus plantarum
BR9607538A BR9607538A (pt) 1995-03-23 1996-03-25 Lactobacilos aderentes ao epitélio
CNB961940867A CN1138551C (zh) 1995-03-23 1996-03-25 上皮粘附性乳杆菌
NO974371A NO974371L (no) 1995-03-23 1997-09-22 Epitelialadhesive lactobacilli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli

Publications (1)

Publication Number Publication Date
SE9501056D0 true SE9501056D0 (sv) 1995-03-23

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli

Country Status (16)

Country Link
US (1) US6159465A (https=)
EP (1) EP0817640B1 (https=)
JP (1) JP4072646B2 (https=)
KR (1) KR100446482B1 (https=)
CN (1) CN1138551C (https=)
AT (1) ATE240738T1 (https=)
AU (1) AU702705B2 (https=)
BR (1) BR9607538A (https=)
CA (1) CA2216150C (https=)
DE (1) DE69628288T2 (https=)
EE (1) EE04097B1 (https=)
ES (1) ES2200057T3 (https=)
NO (1) NO974371L (https=)
PL (1) PL184037B1 (https=)
SE (1) SE9501056D0 (https=)
WO (1) WO1996029083A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
JP2002507997A (ja) * 1997-07-05 2002-03-12 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 腸管細胞によるミネラルの吸収
FI974643L (fi) * 1997-12-30 1999-07-01 Atria Oyj Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
US6830750B1 (en) * 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
CA2378620A1 (en) * 1999-08-09 2001-02-15 Pinaki Panigrahi Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
AP1563A (en) 1999-10-26 2006-02-02 Nestle Sa Lactic acid bacteria for the treatment and /or prophylaxis of giardiasis.
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
CA2450444A1 (fr) * 2001-06-14 2002-12-27 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
EP1730179B1 (en) * 2004-03-23 2010-04-28 Friesland Brands B.V. Novel mannose-specific adhesins and their use
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
EP1931363B1 (en) 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
KR101397386B1 (ko) 2005-12-13 2014-05-26 엑스테라 메디컬 코퍼레이션 혈액으로부터 병원성 미생물, 염증 세포 또는 염증단백질의 체외 제거를 위한 방법
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
ES2861359T3 (es) 2009-12-01 2021-10-06 Exthera Medical Corp Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
CN102905712B (zh) 2010-01-28 2015-12-16 Ab－生物学有限公司 用于治疗肠炎的益生菌组合物
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
EP2861273B1 (en) 2012-06-13 2017-08-23 ExThera Medical Corporation Use of heparin and carbohydrates to treat cancer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
BR112015032134B1 (pt) 2013-06-24 2022-05-10 Exthera Medical Corporation Método de ligação em ponto de extremidade de uma manose não redutora a um substrato e esfera possuindo uma manose ligada em ponto de extremidade
BR112016009827B1 (pt) 2013-11-08 2021-10-26 Exthera Medical Corporation Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
EP3134146B1 (en) 2014-04-24 2024-12-25 ExThera Medical Corporation Method for removing bacteria from blood using high flow rate
US10857283B2 (en) 2014-09-22 2020-12-08 Exthera Medical Corporation Wearable hemoperfusion device
CN108235682A (zh) 2015-09-29 2018-06-29 金伯利-克拉克环球有限公司 用于维护微生物群落的健康平衡的协同组合物
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
KR102769558B1 (ko) 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
KR102024883B1 (ko) 2017-11-24 2019-09-24 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
MY202164A (en) 2018-05-09 2024-04-09 Kobiolabs Inc Lactobacillus paracasei strain and use thereof
KR102138834B1 (ko) 2018-05-23 2020-07-29 주식회사 고바이오랩 락토바실러스 가세리 kbl697 균주 및 그 용도
WO2020231830A1 (en) 2019-05-16 2020-11-19 Exthera Medical Corporation Method for modulating endothelial glycocalyx structure
MY199150A (en) 2019-06-05 2023-10-18 Morinaga Milk Industry Co Ltd Nutritional composition
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (en) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International A composition for treating gastrointestinal disease in animals
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
CA2216150A1 (en) 1996-09-26
BR9607538A (pt) 1998-01-06
EE04097B1 (et) 2003-08-15
WO1996029083A1 (en) 1996-09-26
NO974371L (no) 1997-11-20
PL322550A1 (en) 1998-02-02
ATE240738T1 (de) 2003-06-15
EE9700329A (et) 1998-06-15
CA2216150C (en) 2008-01-22
NO974371D0 (no) 1997-09-22
EP0817640B1 (en) 2003-05-21
PL184037B1 (pl) 2002-08-30
CN1185111A (zh) 1998-06-17
KR100446482B1 (ko) 2006-01-27
CN1138551C (zh) 2004-02-18
EP0817640A1 (en) 1998-01-14
AU702705B2 (en) 1999-03-04
AU5166596A (en) 1996-10-08
ES2200057T3 (es) 2004-03-01
DE69628288T2 (de) 2004-04-08
DE69628288D1 (de) 2003-06-26
JPH11502703A (ja) 1999-03-09
HK1017989A1 (en) 1999-12-10
KR19980703102A (ko) 1998-10-15
JP4072646B2 (ja) 2008-04-09
US6159465A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
SE9501056D0 (sv) Epithelial adherent lactobacilli
Blum et al. Adhesion studies for probiotics: need for validation and refinement
Chauvière et al. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells
Ogawa et al. Inhibition of Streptococcus mutans biofilm formation by Streptococcus salivarius FruA
Jensen et al. In vitro testing of commercial and potential probiotic lactic acid bacteria
Andersson et al. The adhesion of Bacillus cereus spores to epithelial cells might be an additional virulence mechanism
Pithva et al. Probiotic attributes of autochthonous Lactobacillus rhamnosus strains of human origin
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
Delley et al. In vitro activity of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli
AU6040001A (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2613995A (en) Lactobacillus strains of human origin, their compositions and uses thereof
AU2002350530A1 (en) Composition comprising a lactobacillus pentosus strain and uses thereof
EA200101262A1 (ru) Диетическая или фармацевтическая композиция для применения в целях профилактики или лечения гипероксалурии
HUP9901619A1 (hu) Streptococcus thermophilus és bifidobacterium longum baktériumokat tartalmazó enterális diétás kompozíciók és azok alkalmazása
Neilands et al. Parvimonas micra stimulates expression of gingipains from Porphyromonas gingivalis in multi-species communities
SE9501719D0 (sv) Pharmaceutical composition
WO2003039260A3 (en) PROBIOTIC COMPOSITIONS
Akesson et al. Targeting of streptococci by zoocin A
Henriksson et al. Adhesion of Lactobacillus fermentum 104-S to porcine stomach mucus
DK0858501T3 (da) Mælkesyrebakteriepræparater samt deres anvendelse til fremstilling af kolesterolsænkende produkter
Iwamoto et al. The Japanese fermented food natto inhibits sucrose-dependent biofilm formation by cariogenic streptococci
RU94013100A (ru) Штамм lactobacillus helveticus тш, обладающий способностью снижать уровень холестерина в сыворотке крови
AU5069500A (en) Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
Hryniewicz et al. The first national external quality assessment scheme in clinical bacteriology in Poland(POLMicro I)
MD781B1 (en) Selective medium for separation of Streptococcus bacteries